Format

Send to

Choose Destination
Clin Chest Med. 2012 Sep;33(3):531-41. doi: 10.1016/j.ccm.2012.05.004. Epub 2012 Jul 12.

Corticosteroids: still at the frontline in asthma treatment?

Author information

1
Deparment of Pneumology, CHU Liege, GIGAI3 Research Group, University of Liege, Liege, Belgium. R.Louis@chu.ulg.ac.be

Abstract

Inhaled corticosteroids (ICS) have led to improved asthma control and reduced asthma mortality in the Western world. ICS are effective in combating T-helper type 2-driven inflammation featuring mast cell and eosinophilic airway infiltration. Their effect on innate immunity-driven neutrophilic inflammation is poor and their ability to prevent airway remodeling and accelerated lung decline is controversial. Although ICS remain pivotal drugs in asthma management, research is needed to find drugs complementary to the combination ICS/long-acting β2-agonist in refractory asthma and perhaps a new class of drugs as a first-line treatment in mild to moderate noneosinophilic asthma.

PMID:
22929100
DOI:
10.1016/j.ccm.2012.05.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for ORBi (University of Liege)
Loading ...
Support Center